Sonnet Biotherapeutics Holdings, INC Form 4 insider transactions

A Sonnet BioTherapeutics director, Donald J. Griffith, was granted 317 restricted stock units that will vest on January 1, 2025.

John K. Cini, Chief Scientific Officer of Sonnet BioTherapeutics, was granted 1,888 restricted stock units that will vest on January 1, 2025.

Sonnet BioTherapeutics CEO, Pankaj Mohan, was granted 7,554 restricted stock awards, which will vest on January 1, 2025.

Richard T. Kenney, Chief Medical Officer of Sonnet BioTherapeutics, was granted 1,271 restricted stock units that will vest on January 1, 2025.

Sonnet BioTherapeutics' Chief Financial Officer, John Harry Cross III, reported the grant of 1,452 restricted stock units.